Related Experiment Video
Updated: Aug 13, 2026
The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
Published on: April 25, 2012
BMS-193884 and BMS-207940 Bristol-Myers Squibb
Martin Hulpke-Wette1, Reiner Buchhorn
1Department of Pediatric Cardiology, Georg-August-University, Göttingen, Germany.
Abstract:
Bristol-Myers Squibb is developing BMS-193884, an oral endothelin antagonist, for the potential treatment of congestive heart failure (CHF) and pulmonary hypertension [206604]. The compound entered phase I trials in November 1996 [242721] and had progressed to phase II trials [399460], [441398]. Structural modifications led to the development of a second-generation analog, BMS-207940, a biphenylsulfonamide endothelin A receptor-selective antagonist, and the probable discontinuation of the first clinical candidate, BMS-193884 [446511]. By April 2002, BMS-207940 was in phase I trials [446511]. By March 2002, filing for NDA was expected to take place in 2004 at the earliest [452734].
